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Background: Hypoxic-ischaemic injuries such as stroke and traumatic brain injury exhibit features of a distinct
neuro-inflammatory response in the hours and days post-injury. Microglial activation, elevated pro-inflammatory
cytokines and macrophage infiltration contribute to core tissue damage and contribute to secondary injury within a
region termed the penumbra. Type-1 interferons (IFNs) are a super-family of pleiotropic cytokines that regulate
pro-inflammatory gene transcription via the classical Jak/Stat pathway; however their role in hypoxia-ischaemia and
central nervous system neuro-inflammation remains unknown. Using an in vitro approach, this study investigated
the role of type-1 IFN signalling in an inflammatory setting induced by oxygen glucose deprivation (OGD).
Methods: Human BE(2)M17 neuroblastoma cells or cells expressing a type-1 interferon-α receptor 1 (IFNAR1) shRNA
or negative control shRNA knockdown construct were subjected to 4.5 h OGD and a time-course reperfusion period
(0 to 24 h). Q-PCR was used to evaluate IFNα, IFNβ, IL-1β, IL-6 and TNF-α cytokine expression levels. Phosphorylation
of signal transducers and activators of transcription (STAT)-1, STAT-3 and cleavage of caspase-3 was detected by
western blot analysis. Post-OGD cellular viability was measured using a MTT assay.
Results: Elevated IFNα and IFNβ expression was detected during reperfusion post-OGD in parental M17 cells. This
correlated with enhanced phosphorylation of STAT-1, a downstream type-1 IFN signalling mediator. Significantly,
ablation of type-1 IFN signalling, through IFNAR1 knockdown, reduced IFNα, IFNβ, IL-6 and TNF-α expression in
response to OGD. In addition, MTT assay confirmed the IFNAR1 knockdown cells were protected against OGD
compared to negative control cells with reduced pro-apoptotic cleaved caspase-3 levels.
Conclusions: This study confirms a role for type-1 IFN signalling in the neuro-inflammatory response following
OGD in vitro and suggests its modulation through therapeutic blockade of IFNAR1 may be beneficial in reducing
hypoxia-induced neuro-inflammation.
Keywords: Type-1 interferon, Neuro-inflammation, Hypoxia-ischaemia, Cytokines, JAK-StatBackground
Hypoxic-ischaemic brain injury, including stroke and trau-
matic brain injury (TBI), are the most common acute cen-
tral nervous system (CNS) neuro-degenerative disorders
worldwide. Pathologically these injuries begin with an ini-
tial tissue insult and reduction in oxygen and glucose
levels in the surrounding extracellular space, developing a
core infarct. A secondary injury also ensues known as the
penumbra, where neighbouring cells are exposed to the* Correspondence: pcrack@unimelb.edu.au
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unless otherwise stated.microenvironment generated by the core infarct. The de-
velopment of the penumbra is dependent on a host of
physiological processes. Hallmarks of neuro-inflammation
including activated microglia [1], astrogliosis [2], and in-
creased cytokine and chemokine levels [3] have all been
reported in animal models and postmortem human brain
samples of stroke and TBI pathology. In cases of severe
trauma where blood-brain barrier disruption is evident,
peripheral immune cells, namely macrophages and neu-
trophils, have been reported to infiltrate the injury site
and perpetuate an inflammatory response [4,5]. In stroke
pathology, matrix metalloproteinases are released andLtd. This is an Open Access article distributed under the terms of the Creative
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hours of stroke incidence, neutrophils and macrophages
are detected crossing the permeated barrier into the ische-
mic hemisphere [7]. Initially a neuro-inflammatory re-
sponse is beneficial in the clearance of cellular debris and
foreign matter, however, failure to resolve this inflamma-
tion results in greater infarct sizes and poorer prognosis
[8]. The generation of pro-inflammatory mediators within
the CNS occurs through multiple cell types and contrib-
utes to acute neuro-degeneration. Fragmented DNA/
mRNA, heat shock proteins and hyaluronic acid released
from necrotic cells act as ligands for Toll-like receptors
(family of pattern recognition receptors) located in high
density on resident microglia [9-11]. Upon activation,
microglia secrete pro-inflammatory cytokines including
IL-1β, IL-6 and TNF-α [12,13] and this inflammatory mi-
lieu triggers necrosis, apoptosis, necroptosis and excito-
toxicity. The chemokines (C-C motif) ligand-2 (CCL-2)
and CCL-3, also released by microglia, lead to recruitment
of peripheral macrophages and neutrophils [14] driving
a self-perpetuating, neuro-degenerative cytokine storm.
Though microglia are the predominant cell-type responsible
for the development of a CNS inflammatory response, neu-
rons themselves also contribute to this pro-inflammatory
environment. Brain-localised neuronal populations express
TLRs [15,16] and can respond to damage associated mo-
lecular patterns (DAMPs) released in hypoxia-ischaemia
injuries. Downstream signalling upon DAMP recognition
involves modulation of neuronal IL-1β, IL-6 and TNFα
secretion in excitotoxic conditions [17]. Clearly, neu-
rons not only respond to neuro-inflammation but also
secrete pro-inflammatory cytokines themselves. In a
neuro-inflammatory setting, microglia and neurons act
in a symbiotic fashion allowing a cytokine storm to
manifest. In the periphery, type-1 interferons (IFNs) are
key regulators of this cytokine storm [18,19]; however
their role in CNS neuro-inflammation and hypoxic-
ischaemic injury is still not well understood.
Interferons (IFNs) are a super-family of pleiotropic cy-
tokines that play a pivotal role in host immune response
to infections, pathogens and various diseases [20]. The
super-family consists of type-1 (IFNα and IFNβ), type-2
(IFNγ) and type-3 (IFNλ) interferon subtypes which all
possess vastly different functions in innate immunity.
IFNγ is critical in controlling glial phenotype [21] and
peripheral haematopoetic cell infiltration [22] following
in vivo hypoxia-ischaemia insult, which contributes to
the developing penumbra. The roles of type-2 and type-
3 IFNs are not addressed here, rather, this study focuses
on the type-1 IFNs in a neuronal context. Type-1 IFNs
display pro-inflammatory properties via activation of
multiple signalling cascades, heavily dependent on cell
type, including the classical JAK/STAT pathway. Specif-
ically, type-1 IFNs can induce pro-inflammatory genetranscription leading to the secretion of cytokines (in-
cluding TNF-α, IL-6 and IL-1β), cellular recruitment
and inflammatory progression. Indeed their production
is not limited to the periphery with CNS neurons and
microglia known to secrete [23,24] and respond [25] to
type-1 IFNs. Elevated type-1 IFN levels have been re-
ported in various neuro-pathologies including: systemic
lupus erythematosus [26], HIV-encephalopathy [27],
West Nile virus ‘sickness’ [28] and Aicardi-Goutieres
syndrome [29,30]. IFN-α transgenic mice display severe
neuro-degeneration and cognitive decline [31]. However,
the complexities of type-1 production and signalling in
the myriad of cell types within the CNS are still not
clearly understood.
Critically, type-1 IFNs are involved in the initiation
and/or regulation of pro-inflammatory cytokines [18,19]
and in their absence a robust innate immune response
cannot develop. We hypothesised that type-1 IFNs were
therefore critical to the pro-inflammatory cellular re-
sponse following hypoxia-ischaemia insult contributing
to the resulting neuro-degeneration. In this study we
used an in vitro approach to model hypoxic-ischemic in-
jury and characterise a role for type-1 IFNs. We utilised
the human BE(2)M17 neuroblastoma cell line, which ex-
presses mature neuro-filaments, physiologically relevant
levels of tyrosine hydroxylase and dopamine-β-hydroxylase
and conduct neurotransmission [32]. These properties
confer a dopaminergic neuron-like phenotype in a human
cell line, which can be easily genetically manipulated, mak-
ing them a viable candidate to study the effects of OGD.
Using these cultures we identified increased type-1 IFN
production and signalling in response to hypoxic insult,




Primary antibodies used for western blot analysis: rabbit
anti-p-Stat-1 (1:1,000, Cell signalling, 9171S), rabbit anti-
p-Stat-3 (1:1,000, Cell signalling, 9145S), rabbit anti-
cleaved caspase-3 (1:1,000, Cell signalling, 9661S), rabbit
anti-caspase-3 (1:1,000, Cell signalling, 9665S), mouse
anti-β-tubulin (1:20,000, Millipore, MAB3408). Second-
ary antibodies used for western blot analysis: horseradish
peroxidise (HRP) conjugated goat anti-rabbit and goat
anti-mouse (1:1,000, Dako, P0448 and P0447).
M17 neuroblastoma cells
Human BE(2)M17 neuroblastoma cells (ATCC® number:
CRL-2267™) were cultured in T75 flasks with culture
medium (OptiMEM (Gibco), 5% FBS, 0.5% Penicillin-
Streptomycin (Gibco)) at 37°C/5% CO2 until 90% conflu-
ent. Cells were then plated at 1.5 × 106 cells/10 cm dish
or 7.5 × 104 cells/24-well plate and incubated for a
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prior to treatment.
Generation of M17 IFNAR1 overexpressing cells
Transient IFNAR1 overexpressing M17 cells were gener-
ated using a customised IFNAR1 mRNA vector expression
system. An optimised nucleotide sequence encoding
IFNAR1 mRNA (GenBank: NM_010508) was cloned into
a pUC57 vector (GenScript). AttB1 and AttB2 motifs were
then ligated to the IFNAR1 mRNA sequence using PCR
for use in the Gateway® cloning system (Invitrogen). The
AttB1-IFNAR1-AttB2 PCR product was isolated using
QIAquick® PCR purification kits (QIAGEN) after 2%
agarose gel electrophoresis and sequenced. The purified
AttB1-IFNAR1-AttB2 PCR product was then translo-
cated into vector pDONR201 (Invitrogen) using the BP
Clonase© II enzyme kit (Invitrogen), according to manu-
facturer’s guidelines. Upon DH5α bacterial competent
cell expansion (kanamycin selection, 50 μg/mL (Gibco))
and plasmid purification, pDONR-IFNAR1 was obtained.
The IFNAR1 mRNA sequence was removed from the
pDONR201-IFNAR1 plasmid and translocated into a
pcDNA6.2/cEM-GFP destination vector using the LR clo-
nase® II kit (Invitrogen) as per manufacturer’s protocol.
This reaction yields pcDNA6.2/cEM-GFP-IFNAR1 which
upon expansion, purification and sequencing was transi-
ently transfected into parental M17 cells using Fugene®HD
(Promega). Sixty to seventy-five percent transfection effi-
ciency was routinely observed by visual assessment of
GFP positive cells using a Leica DMI 6000B fluorescence
microscope. Fifty-five percent over-expression of IFNAR1
was confirmed using Q-PCR.
Generation of M17 IFNAR1 knockdown cell line
IFNAR1 (IFNAR1 KD) or negative control (NC) knock-
down M17 cells were generated using commercially
available shRNA plasmid constructs (Origene). Briefly,
M17 cells were transfected using Fugene®HD (Promega)
with shRNA plasmids containing an IFNAR1 specific
shRNA cassette or non-effective 29-mer scrambled shRNA
cassette with a GFP tag. Clonal cell lines were generated
using the selectable marker puromycin (0.5 mg/mL, Gibco)
and maintained in OptiMEM containing 10% FBS and 1%
penicillin-streptomycin. Successful knockdown of IFNAR1
expression was confirmed by Q-PCR where IFNAR1 levels
in IFNAR1 KD M17 cells were 80% lower compared to
NC M17 cells.
Interferon α/β treatment
Human IFNα and IFNβ was sourced commercially (PBL
Interferon source, 11200-2 and 11415-1) and dissolved
in a 0.5% BSA/PBS vehicle. Serum starved M17 cell cul-
tures were treated with IFNα, IFNβ (1,000 U/mL) or ve-
hicle for up to 30 min in fresh culture medium.Oxygen glucose deprivation
Serum starved M17 cells were supplemented with
DMEM containing no glucose (Gibco) and gassed with
nitrogen (95% N2, 5% CO2) in a 60% humidified air-tight
chamber for 5 min. This process of OGD routinely
achieved O2 levels of 0% to 1% within the chamber. Cul-
tures were incubated at 37°C within the hypoxic cham-
ber for 4.5 h before being released and supplemented
with high glucose DMEM to model reperfusion for up
to 24 h.
Protein extraction
Cells were scraped in ice cold PBS and centrifuged at
5,000 × g for 5 min. The resulting pellet was then soni-
cated in lysis buffer (50 mM Tris, 1% Triton x-100, 1%
SDS, PhosphoSTOP® and protease inhibitors (Roche),
pH 7.4) and protein concentrations were determined
using a Bradford assay (Biorad).
Western blot analysis
Fifty micrograms of protein extract with 2x Novex® Tris-
glycine SDS sample buffer (Invitrogen) was resolved on
10% acrylamide SDS PAGE gels and transferred to poly-
vinylidene fluoride (PVDF) membranes by semi-dry
transfer. Membranes were blocked with 5% w/v skim
milk in TBS-T for 1 h before overnight incubation with
primary antibodies in 2% w/v skim milk in TBS-T at
4°C. Membranes were then thoroughly washed with fresh
TBS-T prior to being incubated with HRP-conjugated
secondary antibodies (diluted in 2% skim milk in TBS-T)
for 90 min at room temperature. After three further TBS-T
washes, signals were detected using an ECL prime® west-
ern blotting detection kit (Amersham) and visualised
using the IQ350 imaging machine (GE Healthcare). All
western blots were technically repeated twice to confirm
initial results. Post-image densitometry was performed
using Image J software (NIH), whereby signal intensity
was calculated in arbitrary units. For densitometry calcula-
tions, phosphorylation intensity was measured in arbitrary
units and normalised to the β-tubulin loading control.
These values were then calculated as fold change com-
pared to a vehicle control. No ANOVA and post-hoc tests
could be performed as a result of this normalisation
technique.
RNA isolation and cDNA synthesis
Cells were scraped and lysed in TRIzol® (Invitrogen) with
RNA extracted as per manufacturer’s instructions. RNA
yield and purity was determined by the Nanodrop 1000
spectrophotometer (Thermo-scientific). One microgram
RNA was converted to cDNA using a high capacity
cDNA reverse transcription kit (Applied Biosystems) ac-
cording to manufacturer’s guidelines. Reverse transcrip-
tion was performed under the following conditions: 25°C
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minate the reaction. The cDNA product was diluted 1:3
in DEPC-treated H2O for use in Q-PCR.Quantitative polymerase chain reaction (Q-PCR)
All Q-PCR reactions were performed in standard 384-
well plates using the 7,900 ht fast real-time PCR system
(Applied Biosystems). Commercially available Taqman
probes (Applied Biosystems) were used to analyse huIFNα
(Hs00256882_sl), huIFNβ (Hs01077958_sl), huIFNAR1
(Hs01066115_m1), huIL-1β (Hs00174097_m1), huIL-6
(Hs00985639_m1), huTNF-α (Hs00174128_m1) and 18 s
rRNA (4352930E) under the following cycle conditions:
50°C for 2 min, 94.5°C for 10 min (97°C for 30 s, 59.7°C
for 1 min) × 40 repeats. Fold change in mRNA levels were
then calculated using the ΔΔct method (2-ΔΔct) relative to
no OGD control samples. For all Q-PCR plates, samples
were run in triplicate to eliminate potential errors and
variance between wells.MTT assay
Cell viability was measured by the cellular ability to
metabolise 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) (Sigma) to an insoluble purple
formazan product as described previously [33]. All MTT
assays were performed in a 24-well format and conducted
in triplicate. Following OGD, MTT reagent (80 μg/mL)
was added to the cells for 2 h at 37°C. Media was
carefully removed and 200 μL DMSO was added to
each well to solubilise the precipitated formazan product.
This solution was then transferred to a fresh 96-well
plate and absorbance was determined at 595 nm. Via-
bility of treated samples was expressed as a percent-
age of Abs595nm of the no OGD control. For all MTT
assays, cells were plated in triplicate to eliminate po-
tential errors due to differences in cell density or inter-
well absorbance.Statistical analysis
In all MTT assay data an unpaired two-tailed student’s
t-test was used to compare non-transfected M17 and
IFNAR1 overexpression M17 groups, or M17 NC shRNA
and M17 IFNAR1 KD groups where P <0.05 was consid-
ered significant. An unmatched one or two-way ANOVA
was performed, where suitable, for the Q-PCR and densi-
tometry data for each time-point with cellular genotype
or IFN subtype as the fixed variable. A Bonferroni or
Dunnett’s post-hoc test was then performed to determine
significance (P <0.05). Graphical data are represented as
mean ± SEM where each independent experiment is rep-
resented by ‘n’. All statistical analysis was conducted using
PRISM® 5 (GraphPad).Results
Type-1 IFN-dependent phosphorylation of stat isoforms is
subtype specific
Activation of the Jak-Stat signalling cascade leads to robust
pro-inflammatory cytokine secretion and NF-κB phos-
phorylation, hallmarks of classical neuro-inflammation.
Type-1 IFNs activate the Jak-Stat cascade, thus we investi-
gated the ability of type-1 IFNs to phosphorylate Stat iso-
forms in M17 human neuroblastoma cells by western
blot analysis. Cells treated with either IFNα and IFNβ
demonstrated robust tyrosine 701 phosphorylation of
Stat-1 (p-Stat-1) within 10 min (Figure 1A). This phos-
phorylation was sustained for 30 min in IFNβ, not IFNα,
stimulated cultures. Basal levels of p-Stat-1 were undetect-
able in these cultures. Western blot analysis for tyrosine
705 phosphorylation of Stat-3 (p-Stat-3) displayed a nine-
fold increase in IFNβ stimulated cells however this was
not replicated in IFNα cultures (Figure 1B). These data
highlight the ability of type-1 IFNs to signal via the
Jak-Stat pathway in this M17 cell line and identifies
type-1 IFN subtype specificity in the phosphorylation
of this pathway. Specifically, IFNα preferentially in-
duces p-Stat-1 opposed to Stat-3, unlike IFNβ that is
non-selective in its phosphorylation of the Stat iso-
forms analysed.
Oxygen glucose deprivation initiates a
neuro-inflammatory response in M17 cells
Mounting evidence suggests neuro-inflammation is a
key contributor to the severity of CNS hypoxia-ischaemia
injury. To model this hypoxia-ischaemia environment
in vitro we utilised an oxygen glucose deprivation (OGD)
model [34]. To characterise the pro-inflammatory re-
sponse induced by this model we analysed cytokine
expression by Q-PCR. Following reperfusion, M17
cells subjected to 4.5 h of OGD displayed a neuro-
inflammatory response as shown by increased expres-
sion of hallmark pro-inflammatory cytokines. IL-1β
transcripts were elevated 4.2-fold following OGD and
24 h reperfusion compared to control (Figure 2A). At
30 min and 2 h of reperfusion, IL-6 mRNA was up-
regulated 24-fold and 20-fold, respectively (Figure 2B).
Finally, TNFα levels were upregulated 10-fold with 0
h of reperfusion and this elevation was maintained
for 30 min (Figure 2C). Collectively this verifies a ro-
bust and reproducible neuro-inflammatory response
in our model of hypoxia-ischaemia injury, involving
critical pro-inflammatory cytokines known to be dele-
terious to injury outcome.
Type-1 IFN production and signalling plays a role in the
OGD response
An upregulation of key interleukins has been confirmed
in this model of OGD. The JAK-Stat signalling cascade
Figure 1 Type-1 interferon α and β induce differential phosphorylation of Stat isoforms. (A) Representative western blot of IFNα/β
(1,000 U/mL) treated M17 cells probed for P-Stat-1 and corresponding densitometry (*P <0.05, n = 3, unmatched two-way ANOVA, Bonferroni
post-hoc test). (B) Representative western blot of IFNα/β (1,000 U/mL) treated M17 cells probed for P-Stat-3 and corresponding densitometry
(**P <0.01, n = 3, unmatched two-way ANOVA, Bonferroni post-hoc test). For densitometry calculations, phosphorylation intensity was measured
in arbitrary units (A.U.) and normalised to the β-tubulin loading control. Graphical data are represented as mean ± SEM.
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key activators of this pathway and induce phosphoryl-
ation of Stat proteins in the M17 cell line (Figure 1).
Thus to confirm the involvement of type-1 IFN signal-
ling after OGD we investigated production and signal-
ling of type-1 IFNs in response to OGD. Q-PCR showed
a significant 11-fold upregulation in IFNα at 2 h reperfu-
sion (Figure 3A) and 2.3-fold increase in IFNβ at 24 h
reperfusion (Figure 3B). Western blot analysis demon-
strated robust p-Stat-1 at 2 h reperfusion (Figure 3C),
corresponding with the previous upregulation of IFNα at
the same time-point. Conversely, p-Stat-3 levels remained
unchanged across the reperfusion period (Figure 3D).These data support a novel role for type-1 IFN production
and signalling in the neuro-inflammatory response to
OGD in vitro. Moreover, IFNα signalling through Stat-1
appears to be an early activated pathway in this response.
Removal of type-1 IFN signalling reduces
pro-inflammatory cytokine load following OGD
Type-1 IFNs require both IFNAR1 and IFNAR2 subunits
to activate downstream pro-inflammatory signalling cas-
cades. In light of the identification that type-1 IFNs are
novel ligands contributing to neuro-inflammation during
hypoxia-ischaemia insult, we investigated the effect of
removing type-1 IFN signalling through modulation of
Figure 2 Oxygen glucose deprivation (OGD) stimulates a classical innate inflammatory cascade involving an up regulation in IL-1β, IL-6
and TNF-α. M17 cells were subjected to 4.5 h of OGD and reperfused for a 0 to 24 h period. Q-PCR was then performed detecting: (A) IL-1β,
(B) IL-6 and (C) TNFα mRNA levels (*P <0.05, **P <0.01, ***P <0.001, n = 3, unmatched one-way ANOVA, Dunnett’s post-hoc test). Data are
expressed as fold change in mRNA transcript levels in reference to no OGD control samples. Reperfusion times are indicated in hours on the
x axis and graphical data are represented as mean ± SEM.
Figure 3 Type-1 IFN production and signalling plays a role in the cellular response to OGD insult. M17 cells were subjected to 4.5 h
of OGD and reperfused for a 0 to 24 h period. Q-PCR was then performed detecting: (A) IFNα and (B) IFNβ mRNA levels (***P <0.001, n = 3,
unmatched one-way ANOVA, Dunnett’s post-hoc test). Western blot analysis was performed on total cell extracts probing for (C) P-Stat-1 and
(D) P-Stat-3 and corresponding densitometry is shown (**P <0.01, n = 4, unmatched one-way ANOVA, Dunnett’s post-hoc test). For densitometry
calculations, phosphorylation intensity was measured in arbitrary units (A.U.) and normalised to the β-tubulin loading control. Graphical data are
represented as mean ± SEM.
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ther an IFNAR1 knockdown shRNA construct (IFNAR1
KD) or scrambled negative control construct (NC shRNA)
were subjected to 4.5 h of OGD and 0 to 24 h of reperfu-
sion. Q-PCR demonstrated no change in the IL-1β re-
sponse between the two genotypes (Figure 4A). However,
decreased IL-6 (9.7-fold vs. 2.9-fold, 2 h reperfusion,
Figure 4B) and TNFα (8.3-fold vs. 4.5-fold, 0 h reper-
fusion, Figure 4C) mRNA transcript levels were iden-
tified in IFNAR1 KD M17 cells compared with their
NC shRNA counterparts. The IFNAR1 subunit is crit-
ical in permitting autocrine production of the type-1
IFNs through the Jak-Stat signalling cascade. Consid-
ering this, we investigated type-1 IFN production in
response to OGD in the absence of their cognate re-
ceptor subunit IFNAR1. Significantly decreased IFNα
mRNA levels were observed at 2 h (3.5-fold vs. 1.3-fold)
and, although not statistically significant, this trend was
maintained until 4 h (2.1-fold vs. 0.9-fold) reperfusion
in IFNAR1 KD cells compared to NC shRNA cells
(Figure 4D). Significantly, IFNβ levels were decreased
in IFNAR1 KD cells at 2 h (4.5-fold vs. 1.3-fold) and
4 h (3.7-fold vs. 1.4-fold) in comparison to NC shRNA
cells (Figure 4E). These findings suggest that IL-6, TNFα,
IFNα and IFNβ release in response to OGD is medi-
ated by IFNAR1 and subsequent type-1 IFN signalling
cascades.
Type-1 IFN signalling is deleterious in OGD and ablation
of this signalling confers cellular protection
Neuro-inflammation is emerging as an important con-
tributor to neuro-degeneration. The IFNAR1 KD M17
cells display decreased levels of pro-inflammatory cyto-
kines in response to OGD compared to NC shRNA cells.
We therefore assessed the effect of removing type-1 IFN
signalling on cellular viability in response to OGD. The
4.5 h OGD treatment accompanied by 24 h of reperfu-
sion routinely gives 40% to 50% cell death (quantified by
MTT assay previously) in the M17 cell cultures. Our
laboratory has utilised this method of OGD previously
in primary cultured neurons and glia [34]. This longer
period of OGD allows for a combinatorial effect whereby
viable cells not only react to the OGD stimulus but also to
progressive cell death during the reperfusion phase, mod-
elling a penumbra-like environment. Cells transiently
over expressing IFNAR1 display significantly decreased
cell viability (44.9 ± 2.1% vs. 21.6 ± 5.3%) compared to
non-transfected cells in response to OGD (Figure 5A).
Furthermore stable knockdown of IFNAR1 confers signifi-
cant protection following the same insult; 49.0 ± 1.5% vs.
71.6 ± 1.7% cell viability, negative control and IFNAR1
knockdown, respectively (Figure 5B). These viability
alterations related to a 55% over-expression (Figure 5C) or
80% knockdown (Figure 5D) of IFNAR1 in the M17cultures, as quantified by Q-PCR. These findings conclu-
sively show that type-1 IFN signalling irrespective of
ligand subtype is detrimental in hypoxia-ischaemia-
induced neuro-inflammation. Specifically, the IFNAR1
subunit is critical in determining the cell viability out-
come following OGD.Removal of the IFNAR1 subunit confers reductions in
cleaved caspase-3 levels in response to OGD
Within a neuro-inflammatory environment there are
multiple cell death mechanisms activated which contrib-
ute to the overall tissue viability following injury. Necrosis,
apoptosis (extrinsic and intrinsic variants) and necroptosis
have all been reported in hypoxia-ischaemia injury [35].
Our data suggest a protective effect with the removal of
type-1 IFN signalling, through IFNAR1 knockdown, in re-
sponse to OGD. Therefore, we investigated the effects of
removing IFNAR1 on ‘committed’ caspase-3 driven apop-
tosis in this environment. Western blot analysis for
cleaved caspase-3 identified significantly elevated cleavage
at 4 and 24 h reperfusion post OGD in NC shRNA but
not in IFNAR1 KD cultures (Figure 6). This finding high-
lights that removal of type-1 IFN signalling is protective
through mechanisms of reduced committed apoptosis in
response to OGD.Discussion
Reducing the cellular damage within the core infarct
area following hypoxic-ischaemic brain injury is consid-
ered to be largely uncontrollable; however limiting the
development of the penumbra and progression of this
injury may be more achievable. Therapeutic intervention
requires a greater understanding of the cellular processes
occurring in the injured environment, which remain
uncharacterised. Neuro-inflammatory cascades are known
to be involved in the progression of hypoxic-ischaemic in-
jury; however the cytokine profile and cell-specific re-
sponses have not been fully elucidated. Our data suggest a
previously unrecognised role for type-1 IFN production
and signalling in response to OGD insult. IFNα produc-
tion and downstream pro-inflammatory Stat-1 phosphor-
ylation were upregulated during early stage reperfusion
in vitro following OGD treatment. This phenomenon
occurred in a neuro-inflammatory environment where the
hallmark pro-inflammatory cytokines, IL-1β, IL-6 and
TNFα, are readily secreted. Removing type-1 IFN signal-
ling in the IFNAR1 KD cells decreased pro-inflammatory
cytokine release and type-1 IFN levels in response to
OGD. These same cultures were protected from the
hypoxic-ischaemic insult and displayed reduced caspase-3
cleavage. This response was reversed when IFNAR1 over-
expressing cells, promoting type-1 IFN signalling, were ex-
posed to the same conditions.
Figure 4 Removal of type-1 IFN signalling confers a decreased pro-inflammatory response to OGD. M17 NC shRNA and IFNAR1 KD cells
were subjected to 4.5 h of OGD and up to 24 h of reperfusion. Q-PCR was then performed detecting: (A) IL-1β, (B) IL-6, (C) TNFα, (D) IFNα and
(E) IFNβ mRNA levels (*P <0.05, ***P <0.001, n = 5, unmatched two-way ANOVA, Bonferroni post-hoc test). Data are expressed as fold change in
mRNA transcript levels in reference to no OGD control samples. Reperfusion times are indicated in hours on the x axis and graphical data are
represented as mean ± SEM.
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Figure 5 IFNAR1 dependant type-1 IFN signalling is detrimental to cellular viability in response to OGD. M17 cells either (A) over-expressing
IFNAR1 or (B) with IFNAR1 knocked down were subjected to 4.5 h of OGD and 24 h of reperfusion and an MTT assay for cell viability was
performed (*P <0.05, ***P <0.01, n = 4, unpaired two-tailed student’s t-test). Q-PCR was used to quantify IFNAR1 levels in M17 cells transiently
transfected with (C) a pcDNA6.2/cEM-GFP-IFNAR1 over-expression plasmid or stably expressing (D) an IFNAR1 shRNA construct (n = 3). Graphical data
are represented as mean ± SEM.
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and anti-viral roles in peripheral physiology but remain
largely uncharacterised in the CNS. Neurons and glia
are known to produce and respond to type-1 IFNs, how-
ever their role in neuropathologies is still largelyFigure 6 Ablation of type-1 IFN signalling, through removal of IFNAR
GD. M17 NC shRNA and IFNAR1 KD cells were subjected to 4.5 h of OGD a
blot probed for cleaved and total caspase-3 levels (*P <0.05, n = 5, unmatc
as a loading control. For densitometry calculations cleaved caspase-3 inten
Caspase-3: β-actin intensity ratio. These values were then expressed as fold
mean ± SEM. No statistical analysis was performed on the IFNAR1 KD blotsunknown. Among a myriad of signalling cascades, type-
1 IFNs can activate the Jak/Stat pathway and induce
pro-inflammatory gene transcription, however much
about ligand specificity and subsequent Stat isoform
phosphorylation in CNS cell types is still not known.1, decreases pro-apoptotic cleaved-caspase-3 levels following O
nd up to 24 h of reperfusion. Cell lysates were analysed by western
hed one-way ANOVA, Dunnett’s post-hoc test); β-actin was used
sity was measured in arbitrary units (A. U.) and normalised to the
change to the relevant genotype control and are displayed as
as bands remained undetected across all time-points.
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induce differential phosphorylation of Stat isoforms based
on the initial IFN subtype. IFNα displays preference to ac-
tivating Stat-1 as opposed to Stat-3, while IFNβ stimula-
tion of the M17 cultures induced phosphorylation of both
isoforms. This finding gives insight into type-1 IFN ligand
specificity in a CNS-derived cell-line and supports previ-
ous findings that downstream type-1 IFN cascades are se-
lectively activated based on ligand subtype [36,37]. At this
time, 13 subtypes of IFNα alone have been discovered,
with a universal type-1 IFNα used in this study. Therefore,
further characterisation of individual IFNα subtypes is
required.
Microglia are the primary immune cell of the CNS
and play an important role in the final outcome of a
hypoxic-ischaemic injury, however it is equally import-
ant to characterise the contribution and response of
neuronal cells in this environment. Resident CNS cells
secrete inflammatory cytokines IL-6 [12,38], IL-17 [39]
and TNFα [13] within the developing penumbra area.
The M17 neuroblastoma cells used in the current study
have been reported to initiate a neuro-inflammatory re-
sponse upon stimulation with the inflammatory and
neurotoxic peptide amyloid-β (Aβ) 1-42 [40]. This pro-
inflammatory response involved the secretion of type-1
IFN, IL-1β and IL-6. The M17 cell inflammatory re-
sponse and Aβ1-42 cytotoxicity profile resembled that of
primary murine cortical and hippocampal neurons used in
the same study. Mechanisms of TNF-α-induced neurotox-
icity have been repeatedly investigated using the closely
related SH-SY5Y human neuroblastoma cell line. TNF-α
treatment of these cultures induces apoptosis [41,42], as
reported in primary neuronal cultures, with phosphoryl-
ation of NF-κB p65 and Stat proteins being implicated in
the toxicity mechanism [43]. Knockdown of TLR8, up-
stream of these pro-inflammatory molecules, in SH-SY5Y
cultures confers protection against OGD [44]. In the
current study, M17 neuroblastoma cultures subjected to
OGD demonstrated elevated expression of interleukin and
TNF-α during the reperfusion phase. These findings con-
firm that OGD invokes a pro-inflammatory stimulus
within the culture environment. More importantly, the
timing of the cytokine response implies that it is occurring
as a result of the core damage during the OGD period.
We hypothesise that neuro-inflammation exacerbates the
secondary injury and progressive cell death, playing a piv-
otal role in the reperfusion setting.
During periods of ischaemia, tissue undergoes necrosis
[45] and releases cellular debris, detected by TLRs on
microglia, astrocytes and neurons themselves. Ligand
docking to TLR4 leads to direct activation of AP1 and
NFκB transcription factors, leading to cytokine secretion
[46], cellular infiltration and subsequent apoptosis [47].
The type-1 IFNs have been considered the masterregulator of the innate immune systems cytokine re-
sponse signature and hence control the initiation of the
inflammatory response [19]. Taking this into consider-
ation, the timing of a type-1 IFN response is crucial in the
inflammatory response to hypoxic-ischaemic insult. In this
study we demonstrate early upregulation of IFNα during
the reperfusion period and this correlates with increased
Stat-1 phosphorylation at the same 2-h time-point. This
promotes IFNα as a novel CNS cytokine contributing to
the neuro-inflammatory environment stimulated by OGD.
Furthermore the timing of the IFNα response occurs at
the beginning of the inflammatory event, highlighting the
potential to modulate the developing inflammation. The
current study demonstrated an IFNα preferential phos-
phorylation of Stat-1 in M17 cells. We propose that OGD
stimulates IFNα release, selectively phosphorylating Stat-1
and contributes to a deleterious neuro-inflammatory cycle.
Utilising the M17 neuroblastoma cultures, of human ori-
gin, gives insight into cellular inflammatory mechanisms
behind the human brain response to hypoxia-ischaemia.
Despite this characteristic they are indeed oncogenic and
the possibility of an altered type-1 IFN inflammasome,
compared to human cortical neurons, must be taken into
consideration. Basal levels of p-Stat-3 were detected in the
M17 cell cultures with no OGD treatment which may
have masked potential upregulations of this mediator in
response to OGD. Stat-3 is involved in the regulation
of cell cycle [48] and may be altered in the prolifera-
tive M17 cell cultures. Furthermore other interleukins,
namely IL-6, may also engender direct Jak/Stat activation
through gp130 [49] and contribute to neuro-inflammation,
however our data support a novel role for IFNα in per-
petuating this neuro-inflammatory response. This finding
has important implications as the type-1 IFNs are known
to cross-talk with NFκB through regulation of interferon
regulatory factor (IRF) 7 expression [50]. Considering the
importance of NFκB in generating a neuro-degenerative
cytokine ‘storm’, the type-1 IFN signalling cascades may
provide novel avenues for therapeutic development.
Type-1 IFNs require their cognate receptor (interferon
alpha receptor (IFNAR)), comprised of IFNAR1 and
IFNAR2 subunits to bind and signal via the Jak/Stat cas-
cade [18]. Furthermore, studies suggest that the IFNAR1
subunit is responsible for type-1 IFN subtype recogni-
tion and subsequent differential signalling [51,52]. Over-
expression of the IFNAR1 subunit, increasing type-1 IFN
signal transduction, resulted in M17 cells being more
susceptible to OGD induced death. In contrast, knock-
down of the IFNAR1 subunit reversed this detrimen-
tal phenotype with reduced pro-inflammatory cytokines
and subsequent neuro-protection. Uncontrolled neuro-
inflammation is able to facilitate cell death through mul-
tiple degenerative mechanisms including extrinsic and
intrinsic apoptosis. Ablation of type-1 IFN signalling
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of pro-apoptotic cleaved caspase-3 in the OGD envir-
onment. These data suggest that removal of IFNAR1
confers protection through limiting apoptosis, pertin-
ent as caspase-3 pathway inhibitors have been previously
protective in stroke outcome [53]. Thus, we propose that
type-1 IFN signalling is detrimental in hypoxic-ischaemic
injury and modulation of this signalling may be beneficial
to injury outcome. This study demonstrates the net effect
of removing type-1 IFN signalling, however considering
the pleiotropic nature [54,55] of the type-1 IFNs and their
potential for beneficial functions in neuro-inflammation,
a subtype specific functional analysis should be con-
sidered. Furthermore, this study investigates knockdown
of IFNAR1 in M17 neuroblastoma cells alone in the con-
text of OGD. While this approach identifies a critical
neuronal type-1 IFN response in OGD-induced neuro-
degeneration, these cells are normally embedded in a
complex matrix of glial cells and form a cohesive system.
It will be intriguing to identify if this protective phenotype
is maintained in the brain environment where the pres-
ence of astrocytes and microglia enhance the severity of
the cytokine storm in conditions of hypoxia-ischaemia
and, if type-1 IFN signalling is critical in all cell types or
just neurons.
In light of the pleiotropic nature of the type-1 IFNs,
targeting IFNAR1 in the CNS therapeutically should
be addressed with caution. The brain displays a unique
IFNAR expression profile whereby IFNAR1 is readily
expressed [56] but the IFNAR2 subunit is scarce (http://
www.brain-map.org), indicating that peripheral type-1
IFN signalling differs from the CNS. Indeed IFNβ can sig-
nal independent of IFNAR2 [57], which considering the
known receptor subunit imbalance, is crucial to potential
signalling in the brain. These observations highlight that
targeting IFNAR1 alone is a useful tool in controlling
type-1 IFN signalling in the brain and we hypothesise that
therapeutic modulation of this receptor shall prove benefi-
cial in hypoxia-ischaemia injury outcome. However type-1
IFN signalling is crucial in the regulation of innate
immunity, critical in viral immunity, beneficial inflam-
matory responses and protection from autoimmune dis-
ease such as experimental autoimmune encephalomyelitis
[58]. In conditions of brain hypoxia-ischaemia, activation
of innate immune system is required for microglia to suc-
cessfully remove cellular debris from the inflamed envir-
onment and this process is largely considered protective.
Inhibiting IFNAR1-dependent signalling may induce cen-
tral immuno-suppression, which renders this reparative
clearance mechanism inactive, perpetuating tissue damage
and increasing penumbra size. It is clear that timing, de-
gree of modulation, and, cell-type specificity are key fac-
tors in determining the potential therapeutic benefit of
modulating IFNAR1. This study proposes that modulationof neuronal IFNAR1 levels or activity may be beneficial in
controlling cellular damage following hypoxia-ischaemia
injuries.
Neuro-inflammation is a double-edged sword. A deli-
cate balance exists between a protective clearance role,
where inflammation is resolved, and a deleterious role
where unresolved inflammatory processes drive cell
death. We hypothesise that type-1 IFN signalling is a key
process in controlling this neuro-inflammatory environ-
ment and contributes to the deleterious weight of the
neuro-inflammatory fulcrum. We further propose that
modulating type-1 IFN production and/or signalling in
the CNS may enable beneficial immune-modulation and
improve physiological outcome. Clearly a greater body
of knowledge of the neuro-inflammatory cascades gov-
erning neuro-degeneration in hypoxic-ischaemic injuries
is required; however our study supports targeting type-1
IFN signalling as a novel therapeutic strategy.
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